Critical Path Institute

As BIO 2026 approaches, Critical Path Institute is looking forward to connecting with colleagues across industry, academia, patient advocacy, investment, and regulatory science.

BIO is always a valuable opportunity to listen, learn, and explore where collaboration can help address persistent challenges in drug development.

This year, we’re especially interested in conversations around:
➡️ Strategic partnerships that support shared priorities across the biomedical ecosystem
➡️ Translational therapeutic programs and what they need to move toward IND readiness
➡️ Emerging pathways for advanced therapies, including gene, cell, siRNA, A*O, and individualized medicines
➡️ Collaboration with patient advocacy groups and disease foundations to ensure patient needs remain central
➡️ Regulatory science, evidence generation, and collaborative infrastructure that can help reduce development uncertainty

We’re looking forward to thoughtful conversations in San Diego about how partners across the ecosystem can work together to accelerate therapies for patients with unmet medical needs.

If you’ll be attending BIO 2026, we’d welcome the opportunity to connect through the BIO Partnering App.

Be part of the global conversation shaping the future of drug development. The Critical Path Institute’s Global Impact Conference 2026 brings together regulators, industry leaders, scientists, clinicians, those with lived experience, and advocates for three days of high-impact dialogue and collaboration, all focused on accelerating better treatments for patients worldwide.

This is more than a conference — it’s a working forum where ideas turn into action. Join us as we redefine the evidence-generation enterprise for drug development in the 21st century. Through dynamic plenaries and interactive sessions, you’ll engage directly with leaders across the ecosystem on the most pressing challenges and opportunities, including:
- Innovative approaches to patient identification, enrichment, and stratification
- Bridging the gap between drug development and clinical care
- Advancing truly patient-centric clinical trials
- Leveraging real-world data to generate decision-ready evidence
- Integrating novel methodologies to support faster, more effective regulatory decisions

Each day is designed to move beyond discussion, culminating in clear priorities and actionable next steps that continue long after the meeting concludes.

If you are committed to advancing therapies and improving outcomes for patients, CGIC 2026 is where you need to be. Don’t miss your opportunity to connect, collaborate, and help shape what comes next.

Register now during early-bird pricing: https://f.mtr.cool/ypojgnbsop

ICYMI | The Critical Path Institute Podcast: Connecting the Dots in Rare and Pediatric Disease

In this episode of the Critical Path Institute© Podcast, C-Path Vice President of Rare/Orphan and Pediatric Disease Programs Collin Hovinga, joins host and CEO Klaus Romero to discuss the current landscape of rare diseases, the unique challenges and opportunities they present, and how C-Path is uniquely positioned to accelerate drug development for these conditions. This podcast highlights how rare diseases collectively represent a vast and complex group with about 10,000 known rare conditions and numerous subtypes. These differences present challenges, but also opportunities due to shared underlying disease mechanisms.

C-Path’s approach to advancing drug development centers on collaboration among regulators, industry, patient advocacy groups, and researchers, ensuring that patient voices are integral to drug development. A key resource in this ecosystem is the Rare Disease Cures Accelerator-Data and Analytics Platform, a hub that aggregates, standardizes, and curates' diverse data sources such as registries, clinical trials, and natural history studies. The platform enables data reuse to avoid redundant research, supports innovative clinical trial designs, and facilitates regulatory decision-making by providing tools such as trial simulations and alternative control models.

🔗 Listen & subscribe now:
Apple: https://f.mtr.cool/siqcyjnymn
Spotify: https://f.mtr.cool/pgmrmemjml
YouTube: https://f.mtr.cool/vhwambucem

At Critical Path Institute, collaboration, innovation, and sustainability aren't conference themes, they're how we work every day.

Through global public-private partnerships, we bring together industry, regulators, academia, and patient communities to accelerate the development of safe and effective therapies. From advancing regulatory science and data standards to developing tools that improve clinical trial design and decision-making, C-Path's work reflects the same principles driving dialogue at DIA 2026 collaboration that leads to real impact for patients.

Looking forward to engaging with partners at and continuing to move drug development forward, together. Don't miss the opportunity to connect with us at our posters and featured session:
1. Tuesday, June 16 | 111AB | 4:15 PM ET | SESSION "Operationalizing Large Language Models in Drug Development"
2. Wednesday, June 17 | 11:30 AM | POSTER "Glutamate Dehydrogenase (GLDH) as a Safety Biomarker: Applying a Regulatory Science Framework for Drug Development Tools"
3. Wednesday, June 17 | 11:30 AM | POSTER "Privacy-Preserving Federated Analysis Enables International Rare Disease Evidence Generation"

Be part of the global conversation shaping the future of drug development. The Critical Path Institute’s Global Impact Conference 2026 brings together regulators, industry leaders, scientists, clinicians, those with lived experience, and advocates for three days of high-impact dialogue and collaboration, all focused on accelerating better treatments for patients worldwide.

This is more than a conference — it’s a working forum where ideas turn into action. Join us as we redefine the evidence-generation enterprise for drug development in the 21st century. Through dynamic plenaries and interactive sessions, you’ll engage directly with leaders across the ecosystem on the most pressing challenges and opportunities, including:
- Innovative approaches to patient identification, enrichment, and stratification
- Bridging the gap between drug development and clinical care
- Advancing truly patient-centric clinical trials
- Leveraging real-world data to generate decision-ready evidence
- Integrating novel methodologies to support faster, more effective regulatory decisions

Each day is designed to move beyond discussion, culminating in clear priorities and actionable next steps that continue long after the meeting concludes.

If you are committed to advancing therapies and improving outcomes for patients, CGIC 2026 is where you need to be. Don’t miss your opportunity to connect, collaborate, and help shape what comes next.

Register now during early-bird pricing: https://f.mtr.cool/fjvomcowkm

Dive into the world of solutions for Drug Development with C-Path's YouTube channel! Subscribe now for access to on-demand content including meetings, webinars, interviews, and more. Stay informed, stay inspired!

SUBSCRIBE to C-Path's YouTube Channel Now ►► https://f.mtr.cool/ptayoevfof

Interested in C-Path updates? Be sure to subscribe at https://f.mtr.cool/yzxgpnafqa For 20 years, C-Path has been providing vital infrastructure to generate a neutral environment for everyone working in drug development to collaborate, not compete. Let's improve lives, together.